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programming. N Engl J Med 2012;367:2275–83.Special Presentation of Letter and Response:
A Letter to the Editor has been submitted to the Journal by Dr. Jan A.
Staessen and colleagues regarding the paper: Pokushalov E, Romanov
A, Corbucci G, et al. A randomized comparison of pulmonary vein
isolation with versus without concomitant renal artery denervation in
patients with refractory symptomatic atrial ﬁbrillation and resistant
hypertension. J Am Coll Cardiol 2012;60:1163–70. Due to the nature,
detail, and length of the letter and the corresponding reply, the editors
have made a decision to waive the usual word limit and timelines for
letters and replies so as to provide a full airing of the issues for our
readers. However, given the length of the material, we have elected to
place the letter and reply online (onlinejacc.org). We encourage readers
to access this material and trust that it contributes to the editorial
process.No Support for Renal Denervation
in a Meta-Analysis
We read with interest the recent meta-analysis by Davis et al. (1) on
the blood pressure (BP)–lowering effects of renal denervation
(RDN) in treatment-resistant hypertensive patients. The authors
computed pooled statistics for 3 so-called controlled studies and 9
observational studies. They concluded that the 6-month reductions
in systolic/diastolic BP in response to RDN averaged 28.9/11.0 mm
Hg and 25.0/10.0 mm Hg in the controlled and observational
studies, respectively. A number of issues need clariﬁcation.
First, Davis et al. (1) used the term “controlled” to group 2
randomized trials (2,3) and1observational study (4). It is questionable
whether truly randomized trials and a nonrandomized study can be
combined into a single group.Moreover, 1 of the randomized studies
was of low quality (2). Sample size and primary and secondary
endpoints changed across successive design protocols posted at
http://www.clinicaltrials.gov up to 1 year after the paper was pub-
lished (2). We believe that this study (2) should have been excluded
based on CONSORT quality standards (5). Furthermore, the
spread of the BP responses was not reported for the control group in
SYMPLICITY HTN-1 (4). In their Figure 2 (1), the numerical
data for the 6-month systolic responses are switched between 2
studies. Moreover, there is discordance between the SDs reported in
their Figure 2 (systolic/diastolic responses at 6 months, SD 9.8/6.0
mm Hg) and the spread of the BP responses in Figure 5 (4.8/3.0
mm Hg at 6 months) and in the text (5.0/2.0 mm Hg at 12
months) of the paper by Pokushalov et al. (2). Without clariﬁcation,
these observations invalidate the pooled estimates for the controlled
studies in the meta-analysis by Davis et al. (1) because they were
weighted for the inverse of the variance in individual studies.
Second, turning to the 8 uncontrolled studies with 6-month data
reported in Figure 3 of their meta-analysis (1), 6 had a very small
sample size, with follow-up data available in <20 patients (range: 8
to 20 patients). Small studies with positive results are more readily
reported than larger studies with negative results. Davis et al. (1) set
a follow-up rate of <70%, not >70% as stated in their paper, as the
limit to determine a high risk of bias. In fact, the 6-month follow-
up rate in 4 small studies with 10 to 20 participants was 100%, but
in all other studies, it ranged from 53% to 66%. The pooled esti-
mates of the 6-month BP responses in the uncontrolled group were
based on ofﬁce BP in 6 studies and 24-h ambulatory monitoring in
2 studies (6,7). Results based on different techniques of BP
measurement cannot be pooled in a single summary statistic.
One wonders how a meta-analysis including only a single
randomized trial of sufﬁcient quality (3) adds to current knowledge.
Davis et al. (1) concluded that RDN resulted in a substantial BP
reduction at 6 months. In our view, this conclusion does not
hold in view of the above issues. We believe that the main
conclusion of this meta-analysis should have been that currently
the evidence in favor of RDN in treatment-resistant hypertension is
of very low quality, that a meta-analysis cannot replace properly-
sized randomized clinical trials, and that RDN therefore should not
be applied in routine clinical practice.Yu Jin, MD, PhD
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in a Meta-AnalysisWe thank Dr. Jin and colleagues for their comments and interest in
our paper (1). They disagreed with the meta-analysis of data from 2
randomized, controlled trials (RCTs) combined with those from an
observational study in our analysis of controlled studies. Our
decision to pool these data is supported by an opinion paper
published in the American Journal of Epidemiology (2). Moreover,
the pooled data for these 3 studies was consistent; all 3 included
studies demonstrated statistically signiﬁcant beneﬁts with renal
artery denervation (RDN) and their meta-analyses produced I2
measures ranging from 0% to 60%. We agree that the included
studies were of variable quality, but we preferred to include allavailable data. In doing so, we provided the reader with a more
complete understanding of the current state of this literature.
Dr. Jin and colleagues also point out typographical errors in
Figure 2. They are correct that the numbers across the rows for
Symplicity HTN-2 and the Pokushalov et al. (3) study were
inverted for the 6-month systolic blood pressure (BP) analysis.
However, this labeling error had no effect on the results of our meta-
analysis. There was an error in the SD in the study by Pokushalov
et al. (3) in our Figure 2, but re-analysis revealed that this did not
appreciably affect our results. In addition, Jin et al. correctly iden-
tiﬁed a typographical error where the sentence should read “follow-
up rate of <70% at 6 months” instead of “>70%.” With regard to
SYMPLICITY HTN-1, the data were obtained from Table 1,
which included the baseline BP and SD, and Figure 1A, which
provided the change in BP at each time interval with the corre-
sponding 95% conﬁdence interval (4).
We acknowledged in our paper that the available literature con-
sisted of many small studies and discussed the need for further RCTs
in this area. We also acknowledged that the analysis of uncontrolled
studies included studies with ambulatory BP measurements and
studies with ofﬁce BP measurements. This variability in BP
measurement was reported in Table 1 of our paper and was the
rationale behind sensitivity analyses restricted to studies that exam-
ined ambulatory BP response.
The goal of our systematic review andmeta-analysis was to present
and analyze the currently available data regarding the efﬁcacy and
safety of this intervention to allow operators and programs to make
informed decisions regarding the appropriateness of its use in
patients with resistant hypertension. Our conclusion was not that
RDN should be used in routine clinical practice but rather that there
remains a need for large RCTs with long-term follow-up to conﬁrm
and build on the observed efﬁcacy and safety of RDN.Mark I. Davis, MD
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